Market Research Logo

Coronary Stents - Medical Devices Pipeline Assessment, 2018

Coronary Stents - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Coronary Stents - Medical Devices Pipeline Assessment, 2018 provides an overview of Coronary Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Coronary Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Coronary Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Coronary Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Coronary Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Coronary Stents Overview
3 Products under Development
3.1 Coronary Stents - Pipeline Products by Stage of Development
3.2 Coronary Stents - Pipeline Products by Segment
3.3 Coronary Stents - Pipeline Products by Territory
3.4 Coronary Stents - Pipeline Products by Regulatory Path
3.5 Coronary Stents - Pipeline Products by Estimated Approval Date
3.6 Coronary Stents - Ongoing Clinical Trials
4 Coronary Stents - Pipeline Products under Development by Companies
4.1 Coronary Stents Companies - Pipeline Products by Stage of Development
4.2 Coronary Stents - Pipeline Products by Stage of Development
5 Coronary Stents Companies and Product Overview
5.1 480 Biomedical Inc Company Overview
5.2 Aachen Resonance GmbH Company Overview
5.3 Abbott Vascular Inc Company Overview
5.4 Adcomp Technologies Inc. Company Overview
5.5 Advanced Bifurcation Systems Inc Company Overview
5.6 Aeon Bioscience Company Overview
5.7 AlviMedica Medical Technologies Inc. Company Overview
5.8 Amaranth Medical Inc Company Overview
5.9 Arterius Ltd Company Overview
5.10 Atrium Medical Corp Company Overview
5.11 Axordia Ltd (Inactive) Company Overview
5.12 B. Braun Melsungen AG Company Overview
5.13 Bionext Biotech Products Ltd. Company Overview
5.14 Biosensors International Group Ltd Company Overview
5.15 Biosten, LLC Company Overview
5.16 Biotronik AG Company Overview
5.17 Biotronik SE & Co KG Company Overview
5.18 Boston Scientific Corp Company Overview
5.19 Cardionovum GmbH Company Overview
5.20 Cardiorev Pte Ltd (Inactive) Company Overview
5.21 Columbia University Company Overview
5.22 Contego Medical, LLC Company Overview
5.23 Cordis Corp Company Overview
5.24 Cytograft Tissue Engineering Inc (Inactive) Company Overview
5.25 DISA Vascular (Pty) Ltd Company Overview
5.26 Elixir Medical Corp Company Overview
5.27 Envision Scientific Pvt. Ltd Company Overview
5.28 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
5.29 I.B.S. S.p.A. Company Overview
5.30 Icon Interventional Systems, Inc. Company Overview
5.31 ID Nest Medical SAS Company Overview
5.32 InspireMD Inc Company Overview
5.33 Japan Stent Technology Co., Ltd. Company Overview
5.34 Kaneka Corp Company Overview
5.35 Kyoto Medical Planning Co Ltd Company Overview
5.36 Lepu Medical Technology (Beijing) Co Ltd Company Overview
5.37 Liaoning Biomedical Materials R&D Center Co Ltd Company Overview
5.38 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
5.39 MangoGen Pharma Inc Company Overview
5.40 Manli Cardiology Ltd Company Overview
5.41 Medinol Ltd Company Overview
5.42 Medlogics Device Corp (Inactive) Company Overview
5.43 Medtronic plc Company Overview
5.44 Meril Life Sciences Pvt Ltd Company Overview
5.45 Miami Cardiovascular Innovations Company Overview
5.46 Micell Technologies Inc Company Overview
5.47 Michigan Technological University Company Overview
5.48 MicroPort Scientific Corp Company Overview
5.49 Minvasys SAS Company Overview
5.50 MIV Therapeutics Inc Company Overview
5.51 NanoCoeur, Inc. Company Overview
5.52 Nanova, Inc Company Overview
5.53 National University of Ireland Galway Company Overview
5.54 Nesstent Ltd. Company Overview
5.55 Nexeon MedSystems Inc Company Overview
5.56 North Carolina State University Company Overview
5.57 Northwestern University Company Overview
5.58 NuVascular Technologies Inc Company Overview
5.59 OrbusNeich Company Overview
5.60 Palmaz Scientific Inc (Inactive) Company Overview
5.61 Pediastent LLC Company Overview
5.62 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.63 Qvanteq AG Company Overview
5.64 Relisys Medical Devices Ltd Company Overview
5.65 REVA Medical Inc Company Overview
5.66 Rontis AG Company Overview
5.67 S3V Vascular Technologies Company Overview
5.68 Sahajanand Medical Technologies Pvt Ltd Company Overview
5.69 Shanghai MicroPort Medical Group Co Ltd Company Overview
5.70 Sino Medical Sciences Technology Inc Company Overview
5.71 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview
5.72 Stentys SA Company Overview
5.73 Svelte Medical Systems Inc Company Overview
5.74 Tepha Inc Company Overview
5.75 Terumo Corp Company Overview
5.76 TissueGen Inc Company Overview
5.77 TrendyMED Inc. Company Overview
5.78 University of Alabama at Birmingham Company Overview
5.79 University of Colorado Company Overview
5.80 University of Florida Company Overview
5.81 University of Gottingen Company Overview
5.82 University of Michigan Company Overview
5.83 University of Strathclyde Company Overview
5.84 University of Utah Company Overview
5.85 Vascular Concepts Ltd Company Overview
5.86 VasoTech Inc. Company Overview
5.87 Vornia Biomaterials Ltd Company Overview
5.88 Xenogenics Corporation Company Overview
6 Coronary Stents- Recent Developments
6.1 May 24, 2018: Reva Symposium Showcases Clinical Data
6.2 May 24, 2018: Independent Stent Imaging Study Shows Excellent Healing Profile with Resolute Onyx DES in Complex Patients with Coronary Artery Disease
6.3 May 24, 2018: Terumo to Launch the Ultimaster Tansei Drug Eluting Stent in Europe
6.4 May 24, 2018: New Data Presented at EuroPCR Confirms Orsiro’s Position as a Leading DES
6.5 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.6 May 23, 2018: Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy
6.7 May 23, 2018: Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
6.8 May 23, 2018: CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018
6.9 May 23, 2018: Positive Two-Year Data from MiStent DESSOLVE III Trial Presented at EuroPCR - Excellent Safety And Low Target Lesion Revascularization (TLR) Rates Persist
6.10 May 23, 2018: Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium
6.11 May 23, 2018: Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy
6.12 May 23, 2018: MicroPort's Firehawk Drug Eluting Stent Achieves Primary Endpoint and Shows Very Promising Results From TARGET All-Comers Clinical Trial
6.13 May 23, 2018: BIOTRONIK Announces Further Investment into Magmaris, Its Unique Resorbable Magnesium Scaffold Program
6.14 May 22, 2018: PCR statement on Chronic Coronary Syndromes
6.15 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC
6.16 May 16, 2018: Reva Announces First Implant Of The Fantom Bioresorbable Scaffold In Turkey
6.17 May 16, 2018: InspireMD Receives Regulatory Approval for both CGuard EPS and MGuard Prime in Ecuador
6.18 May 16, 2018: Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease
6.19 May 16, 2018: Surmodics Announces Leadership Change and Appointment of Interim CFO
6.20 May 15, 2018: Saama Technologies and ICON Commercialization and Outcomes Partner to Unlock The Value of Real World Evidence
6.21 May 15, 2018: Asahi Intecc Group announces financial results and presentation materials for the 3rd Quarter of the fiscal year ending June 2018.
6.22 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow
6.23 May 09, 2018: Reva Medical Announces First Quarter 2018 Financial Results
6.24 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.25 May 02, 2018: Abbott’s XIENCE Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
6.26 May 02, 2018: Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
6.27 May 02, 2018: CORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
6.28 May 02, 2018: ICON Reports First Quarter 2018 Results
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Coronary Stents - Pipeline Products by Stage of Development
Table 2: Coronary Stents - Pipeline Products by Segment
Table 3: Coronary Stents - Pipeline Products by Territory
Table 4: Coronary Stents - Pipeline Products by Regulatory Path
Table 5: Coronary Stents - Pipeline Products by Estimated Approval Date
Table 6: Coronary Stents - Ongoing Clinical Trials
Table 7: Coronary Stents Companies - Pipeline Products by Stage of Development
Table 8: Coronary Stents - Pipeline Products by Stage of Development
Table 9: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Absorbable Scaffold Stent - Neonatal Aortic Coarctation - Product Status
Table 11: Absorbable Scaffold Stent - Neonatal Aortic Coarctation - Product Description
Table 12: Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 13: ARtax Coronary Stent - Product Status
Table 14: ARtax Coronary Stent - Product Description
Table 15: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 16: Second Generation Bioresorbable Vascular Scaffold - Product Status
Table 17: Second Generation Bioresorbable Vascular Scaffold - Product Description
Table 18: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
Table 19: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
Table 20: XIENCE Thin man DES - Product Status
Table 21: XIENCE Thin man DES - Product Description
Table 22: ZoMaxx Drug Eluting Coronary Stent System - Product Status
Table 23: ZoMaxx Drug Eluting Coronary Stent System - Product Description
Table 24: Abbott Vascular Inc - Ongoing Clinical Trials Overview
Table 25: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Table 26: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Table 27: Xience SBA Everolimus Eluting Coronary Stent System - Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
Table 28: Xience SBA Everolimus Eluting Coronary Stent System - Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study
Table 29: Xience SBA Everolimus Eluting Coronary Stent System - XIENCE Short DAPT Study
Table 30: XIENCE Thin man DES - XIENCE Short DAPT Study
Table 31: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Dual Drug Eluting Stent - Product Status
Table 33: Dual Drug Eluting Stent - Product Description
Table 34: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Stenting System - Bare Metal Stent - Product Status
Table 36: Stenting System - Bare Metal Stent - Product Description
Table 37: Stenting System - Drug Eluting Stent - Product Status
Table 38: Stenting System - Drug Eluting Stent - Product Description
Table 39: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Drug Eluting Stent - Product Status
Table 41: Drug Eluting Stent - Product Description
Table 42: AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 43: BMS - Avantgarde - Product Status
Table 44: BMS - Avantgarde - Product Description
Table 45: Cre8 DES - Product Status
Table 46: Cre8 DES - Product Description
Table 47: DES - Coracto - Product Status
Table 48: DES - Coracto - Product Description
Table 49: Janus Flex - Product Status
Table 50: Janus Flex - Product Description
Table 51: Optima Jet - Product Status
Table 52: Optima Jet - Product Description
Table 53: AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview
Table 54: Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
Table 55: Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
Table 56: Cre8 DES - A Prospective, Single Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
Table 57: Cre8 DES - Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients
Table 58: Cre8 DES - Second-generation Drug-eluting Stents in Diabetes: A Randomized Trial: The SUGAR Trial
Table 59: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 60: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status
Table 61: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description
Table 62: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 63: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 64: FORTITUDE Scaffold - Product Status
Table 65: FORTITUDE Scaffold - Product Description
Table 66: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 67: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 68: Second Generation FORTITUDE Scaffold - Product Status
Table 69: Second Generation FORTITUDE Scaffold - Product Description
Table 70: Amaranth Medical Inc - Ongoing Clinical Trials Overview
Table 71: FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
Table 72: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
Table 73: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
Table 74: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
Table 75: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
Table 77: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
Table 78: Atrium Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 79: Next Generation Super Flexible Cobalt Chromium Coronary Stent - Product Status
Table 80: Next Generation Super Flexible Cobalt Chromium Coronary Stent - Product Description
Table 81: Axordia Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 82: Regenerative Stent - Product Status
Table 83: Regenerative Stent - Product Description
Table 84: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
Table 85: Coroflex DEBlue - Product Status
Table 86: Coroflex DEBlue - Product Description
Table 87: Bionext Biotech Products Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 88: Biostent - Product Status
Table 89: Biostent - Product Description
Table 90: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 91: BioFreedom Drug Coated Stent - Product Status
Table 92: BioFreedom Drug Coated Stent - Product Description
Table 93: Excel II DES - Product Status
Table 94: Excel II DES - Product Description
Table 95: Sparrow Drug Eluting Stent System - Product Status
Table 96: Sparrow Drug Eluting Stent System - Product Description
Table 97: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
Table 98: BioFreedom Drug Coated Stent - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
Table 99: BioFreedom Drug Coated Stent - A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
Table 100: BioFreedom Drug Coated Stent - A Randomized Multicenter Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions
Table 101: BioFreedom Drug Coated Stent - A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
Table 102: BioFreedom Drug Coated Stent - BioFreedom PK Study in Patients with CAD Who Receive the BioFreedom Biolimus A9 Stent
Table 103: BioFreedom Drug Coated Stent - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 104: BioFreedom Drug Coated Stent - Prospective Multi center Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients with Coronary Artery Disease (Biofreedom Registry)
Table 105: BioFreedom Drug Coated Stent - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
Table 106: BioFreedom Drug Coated Stent - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
Table 107: BioFreedom Drug Coated Stent - To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom BA9 Drug Coated Coronary Stent in Patients with Native, de Novo Coronary Artery Disease
Table 108: Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial)
Table 109: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 110: Biodegradable Endovascular Implant - Product Status
Table 111: Biodegradable Endovascular Implant - Product Description
Table 112: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
Table 113: Coronary Stent System - Product Status
Table 114: Coronary Stent System - Product Description
Table 115: Magmaris Bioresorbable Magnesium Scaffold - Product Status
Table 116: Magmaris Bioresorbable Magnesium Scaffold - Product Description
Table 117: Orsiro Hybrid Drug Eluting Stent - Product Status
Table 118: Orsiro Hybrid Drug Eluting Stent - Product Description
Table 119: Biotronik AG - Ongoing Clinical Trials Overview
Table 120: Orsiro Hybrid Drug Eluting Stent - A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-eluting Stent with a Durable Polymer Everolimus-eluting Stent for Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Table 121: Orsiro Hybrid Drug Eluting Stent - A Randomized Comparison of a Sirolimus-eluting Stent with Biodegradable Polymer Versus an Everolimus-eluting Stent with a Durable Polymer for Percutaneous Coronary Revascularization
Table 122: Orsiro Hybrid Drug Eluting Stent - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial with Stent Evaluation in All-comers IV (TWENTE IV)
Table 123: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment of Subjects with up to Three De Novo or Restenotic Coronary Artery Lesions - V
Table 124: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III
1.2 List of Figures
Figure 1: Coronary Stents - Pipeline Products by Stage of Development
Figure 2: Coronary Stents - Pipeline Products by Segment
Figure 3: Coronary Stents - Pipeline Products by Territory
Figure 4: Coronary Stents - Pipeline Products by Regulatory Path
Figure 5: Coronary Stents - Pipeline Products by Estimated Approval Date
Figure 6: Coronary Stents - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report